LB Pharmaceuticals Inc Common Stock
LBRX · NASDAQ
9/30/2025 | 6/30/2025 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | – | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $81 | – | $5 | $0 |
| Gross Profit | -$81 | – | -$5 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,419 | – | $10,664 | $24,460 |
| G&A Expenses | $0 | – | $0 | $2,120 |
| SG&A Expenses | $2,746 | – | $5,414 | $2,120 |
| Sales & Mktg Exp. | $0 | – | $0 | $0 |
| Other Operating Expenses | $0 | – | $0 | $0 |
| Operating Expenses | $5,165 | – | $16,078 | $26,580 |
| Operating Income | -$5,246 | – | -$16,083 | -$26,580 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,690 | – | $1,902 | -$1,116 |
| Pre-Tax Income | -$3,556 | – | -$14,181 | -$27,696 |
| Tax Expense | $0 | – | $0 | $0 |
| Net Income | -$3,556 | – | -$14,181 | -$27,696 |
| % Margin | – | – | – | – |
| EPS | -0.14 | – | -0.63 | -7.82 |
| % Growth | – | – | 91.9% | – |
| EPS Diluted | -0.14 | – | -0.63 | -7.82 |
| Weighted Avg Shares Out | 25,299 | – | 22,443 | 3,540 |
| Weighted Avg Shares Out Dil | 25,299 | – | 22,443 | 3,540 |
| Supplemental Information | – | – | – | – |
| Interest Income | $707 | – | $384 | $411 |
| Interest Expense | $0 | – | $0 | $0 |
| Depreciation & Amortization | $81 | – | $5 | $3 |
| EBITDA | -$3,475 | – | -$14,176 | -$27,051 |
| % Margin | – | – | – | – |